Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days
The Times: The headline rate of inflation fell more than expected in November to a 10-month low – increasing expectations that the Bank of England will cut interest rates tomorrow. The
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society
The FTSE 100 closed the week down 0.6% after data from the Office for National Statistics showed the UK economy contracted by 0.1%. European markets also finished in negative territory,
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
Welcome to the Avetix Group YouTube channel.
In commodities this week, momentum continued to build, with silver prices spiking to a new high of $56.72 per ounce after a 10-hour halt in Comex trading, caused by a cooling
Zak Mir takes a look at the latest charting requests. Today’s selection includes Avacta, EnergyPathways, Fulcrum, First Class Metals, and Kodal Minerals.
London’s FTSE 100 closed at its lowest level in almost two weeks on Friday, dragged lower by steep losses in property and travel stocks. The blue-chip index ended 53 points,
Zak Mir takes a charting look at the latest requested stocks. Today’s selection includes Avacta, Greatland, and Mosman.
UK stock markets closed lower on Friday, easing back after a record-breaking October rally as investors adopted a more cautious stance ahead of the Bank of England’s monetary policy decision and the Government’s Budget this month.
Solvonis Therapeutics (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (“CNS”) disorders, announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.